Cannabidiol (CBD) receives Notice of Allowance for EU patent for the prevention and treatment of graft-versus-host disease (GvHD)

On the 2nd of October 2019, the European Patent Office has issued a Notice of Allowance for EU Patent for the use of cannabidiol ((CBD) a non-psychoactive component of cannabis with immunosuppressive properties) for the prevention and treatment of acute graft-versus-host disease (aGvHD).1 There are currently no approved therapies for the prevention and very few licensed drugs for the treatment of aGvHD. Therefore, the development of efficient therapies to prevent and treat aGvHD is a major goal of allogeneic bone marrow transplantation.2

The company has stated that the new, proprietary CBD product which is an oral formulation in olive oil, that was designed to overcome previous issues of poor oral bioavailability and stability, has the potential to be used as a treatment option for bone marrow transplant recipients who are at high risk of developing aGvHD.1 CBD has previously been granted orphan drug designation by both, the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the results for the phase II study (NCT03840512) was previously covered by the GvHD hub.

  1. Globenewswire. Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease. [Accessed 02 October 2019]
  2. Myeloma Research News. Kalytera’s Cannabidiol Prevents Graft-Versus-Host-Disease After Bone Marrow Transplant, Data Show.[Accessed 02 October 2019]
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative